Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19
Summary Previously, we and others have shown that SARS-CoV-2 spike-specific IgG antibodies play a major role in disease severity in COVID-19 by triggering macrophage hyperactivation, disrupting endothelial barrier integrity, and inducing thrombus formation. This hyper-inflammation is dependent on high levels of anti-spike IgG with aberrant Fc tail glycosylation, leading to Fcγ receptor hyper-activation. For development of immune-regulatory therapeutics, drug specificity is crucial to counteract excessive inflammation while simultaneously minimizing inhibition of antiviral immunity. We here developed anin vitroactivation assay to screen for small molecule drugs that specifically counteract antibody-induced pathology. We identified that anti-spike induced inflammation is specifically blocked by small molecule inhibitors against SYK and PI3K. We identified SYK inhibitor entospletinib as the most promising candidate drug, which also counteracted anti-spike-induced endothelial dysfunction and thrombus formation. Moreover, entospletinib blocked inflammation by different SARS-CoV-2 variants of concern. Combined, these data identify entospletinib as a promising treatment for severe COVID-19.Graphical abstract <jats:fig id="ufig1" position="float" fig-type="figure" orientation="portrait"><jats:graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="521247v1_ufig1" position="float" orientation="portrait" /></jats:fig>.
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 23. Dez. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Geyer, Chiara E. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.12.20.521247 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI038240610 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI038240610 | ||
| 003 | DE-627 | ||
| 005 | 20230429100432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221222s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.12.20.521247 |2 doi | |
| 035 | |a (DE-627)XBI038240610 | ||
| 035 | |a (biorXiv)10.1101/2022.12.20.521247 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Geyer, Chiara E. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary Previously, we and others have shown that SARS-CoV-2 spike-specific IgG antibodies play a major role in disease severity in COVID-19 by triggering macrophage hyperactivation, disrupting endothelial barrier integrity, and inducing thrombus formation. This hyper-inflammation is dependent on high levels of anti-spike IgG with aberrant Fc tail glycosylation, leading to Fcγ receptor hyper-activation. For development of immune-regulatory therapeutics, drug specificity is crucial to counteract excessive inflammation while simultaneously minimizing inhibition of antiviral immunity. We here developed anin vitroactivation assay to screen for small molecule drugs that specifically counteract antibody-induced pathology. We identified that anti-spike induced inflammation is specifically blocked by small molecule inhibitors against SYK and PI3K. We identified SYK inhibitor entospletinib as the most promising candidate drug, which also counteracted anti-spike-induced endothelial dysfunction and thrombus formation. Moreover, entospletinib blocked inflammation by different SARS-CoV-2 variants of concern. Combined, these data identify entospletinib as a promising treatment for severe COVID-19.Graphical abstract <jats:fig id="ufig1" position="float" fig-type="figure" orientation="portrait"><jats:graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="521247v1_ufig1" position="float" orientation="portrait" /></jats:fig> | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Chen, Hung-Jen |e verfasserin |4 aut | |
| 700 | 1 | |a Bye, Alexander P. |e verfasserin |4 aut | |
| 700 | 1 | |a Manz, Xue D. |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Caniels, Tom G. |e verfasserin |4 aut | |
| 700 | 1 | |a Bijl, Tom P.L. |e verfasserin |4 aut | |
| 700 | 1 | |a Griffith, Guillermo R. |e verfasserin |4 aut | |
| 700 | 1 | |a Hoepel, Willianne |e verfasserin |4 aut | |
| 700 | 1 | |a de Taeye, Steven W. |e verfasserin |4 aut | |
| 700 | 1 | |a Veth, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Vlaar, Alexander P.J. |e verfasserin |4 aut | |
| 700 | 1 | |a Vidarsson, Gestur |e verfasserin |4 aut | |
| 700 | 1 | |a Bogaard, Harm Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Aman, Jurjan |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbins, Jonathan M. |e verfasserin |4 aut | |
| 700 | 1 | |a van Gils, Marit J. |e verfasserin |4 aut | |
| 700 | 1 | |a de Winther, Menno P.J. |e verfasserin |4 aut | |
| 700 | 1 | |a Dunnen, Jeroen den |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 23. Dez. |
| 773 | 1 | 8 | |g year:2022 |g day:23 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.12.20.521247 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 23 |c 12 | ||